Integrative healthcare solution for schizophrenic and depressive disorders

For the first time scientific research has shown that levels of IL-6, IL-18, TNFα, and sIL-2R are elevated in Major depression Disorder (MDD) and schizophrenic patients. Il-18 is important in regulating immune function. Furthermore, patients in the ‘schizophrenia group’ showed higher levels of the inflammatory markers than MDD and control groups.

The study authors Al-Hakeim et al concluded that the immunological response in the MDD and schizophrenic patients groups was significantly stimulated and that these disorders may be considered an inflammatory disorder because of elevated levels of proinflammatory cytokines in spite of lacking an overt inflammation.

Furthermore they suggested and Integrative healthcare solution of using anti-inflammatory drugs as adjuvant therapy in schizophrenic and depressive disorders.